Sangamo Therapeutics
SGMO
$0.49
Share price
-5.36%
Change (1 day)
-70.12%
Change (1 year)
Operating Margin for Sangamo Therapeutics (SGMO)
Operating Margin as of April 2024 (TTM): -160.78%
According to Sangamo Therapeutics 's latest financial reports and stock price the company's current Operating Margin is -160.78%. At the end of 2021 the company had an Operating Margin of -160.79%.
Operating Margin history for Sangamo Therapeutics from 2001 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | -160.79% | 57.34% |
| 2020 | -102.19% | 9.69% |
| 2019 | -93.16% | 14.2% |
| 2018 | -81.57% | -45.34% |
| 2017 | -149.23% | -59.63% |
| 2016 | -369.65% | 214.82% |
| 2015 | -117.42% | 103.88% |
| 2014 | -57.59% | -47.8% |
| 2013 | -110.32% | 7.3% |
| 2012 | -102.81% | -70.38% |
| 2011 | -347.14% | 189.64% |
| 2010 | -119.85% | 37.05% |
| 2009 | -87.45% | -44.22% |
| 2008 | -156.77% | -42.42% |
| 2007 | -272.27% | 3.57% |
| 2006 | -262.89% | -52.5% |
| 2005 | -553.46% | -50.32% |
| 2004 | -1,114.07% | 144.13% |
| 2003 | -456.34% | -36.47% |
| 2002 | -718.26% | 128.15% |
| 2001 | -314.82% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 22.88% | -114.23% | 🇺🇸 USA |
 Amgen AMGN | 34.59% | -121.51% | 🇺🇸 USA |
 Biogen BIIB | 31.30% | -119.47% | 🇺🇸 USA |
 Dow DOW | 4.98% | -103.10% | 🇺🇸 USA |
 Gilead Sciences GILD | 26.84% | -116.69% | 🇺🇸 USA |
 Merck MRK | 27.73% | -117.25% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -108.63% | -32.44% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 4.83% | -103.00% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.